Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.

Arhin FF, Draghi DC, Pillar CM, Parr TR Jr, Moeck G, Sahm DF.

Antimicrob Agents Chemother. 2009 Nov;53(11):4762-71. doi: 10.1128/AAC.00952-09. Epub 2009 Sep 8.

2.

Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.

McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T Jr, Moeck G.

J Antimicrob Chemother. 2009 Jun;63(6):1191-9. doi: 10.1093/jac/dkp126. Epub 2009 Apr 15.

PMID:
19369269
3.

Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011.

Morrissey I, Seifert H, Canton R, Nordmann P, Stefani S, Macgowan A, Janes R, Knight D; Oritavancin Study Group..

J Antimicrob Chemother. 2013 Jan;68(1):164-7. doi: 10.1093/jac/dks344. Epub 2012 Aug 30.

PMID:
22941898
4.

European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.

Felmingham D, Brown DF, Soussy CJ.

Diagn Microbiol Infect Dis. 1998 Aug;31(4):563-71.

PMID:
9764397
5.

In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.

Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF.

Int J Antimicrob Agents. 2015 Dec;46(6):674-81. doi: 10.1016/j.ijantimicag.2015.08.014. Epub 2015 Oct 20.

PMID:
26541881
6.

Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.

Jones RN, Turnidge JD, Moeck G, Arhin FF, Mendes RE.

Antimicrob Agents Chemother. 2015 Apr;59(4):2405-9. doi: 10.1128/AAC.05098-14. Epub 2015 Feb 9.

7.

Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).

Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN.

J Antimicrob Chemother. 2015 Feb;70(2):498-504. doi: 10.1093/jac/dku421. Epub 2014 Oct 31.

PMID:
25362568
8.

Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.

Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.

Antimicrob Agents Chemother. 2008 Jul;52(7):2383-8. doi: 10.1128/AAC.01641-07. Epub 2008 Apr 28.

9.

In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.

Karlowsky JA, Walkty AJ, Baxter MR, Adam HJ, Zhanel GG.

Diagn Microbiol Infect Dis. 2014 Dec;80(4):311-5. doi: 10.1016/j.diagmicrobio.2014.09.003. Epub 2014 Sep 16.

PMID:
25294303
11.
13.

Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010.

Mendes RE, Woosley LN, Farrell DJ, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2012 Mar;56(3):1639-42. doi: 10.1128/AAC.06067-11. Epub 2011 Dec 19.

14.

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.

Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.

J Antimicrob Chemother. 2008 Jul;62(1):116-21. doi: 10.1093/jac/dkn124. Epub 2008 Apr 19.

PMID:
18424792
16.

[Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].

Loza E, Morosini MI, Pascual A, Tubau F, Alcalá J, Liñares J, Hernández-Bello JR, Baquero F, Perea E, Martín R, Jones RN, Cantón R; SENTRY Surveillance Program, Spain (2002-2006)..

Enferm Infecc Microbiol Clin. 2008 Oct;26(8):489-94. Spanish.

PMID:
19094861
17.
19.
20.

Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.

Sader HS, Jones RN, Ballow CH, Biedenbach DJ, Cered RF; GSMART Latin America Study Group..

Braz J Infect Dis. 2001 Feb;5(1):21-31.

PMID:
11290311

Supplemental Content

Support Center